Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Treace Medical Concepts, Inc. reported revenue of $213M, up 1.6% year over year. Operating margin was -25.5% and net margin -27.7%, on a free-cash-flow margin of -13.9% with capital expenditure at 6.4% of revenue. Every figure is computed directly from TMCI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $213M | -25.5% | -27.7% |
| FY2024 | $209M | -26.6% | -26.6% |
| FY2023 | $187M | -27.5% | -26.5% |
| FY2022 | $142M | -24.6% | -30.2% |
| FY2021 | $94M | -17.5% | -21.8% |
How does TMCI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.